In last trading session, Bristol-Myers Squibb Co (NYSE:BMY) saw 13.01 million shares changing hands with its beta currently measuring 0.38. Company’s recent per share price level of $47.17 trading at $0.74 or 1.59% at ring of the bell on the day assigns it a market valuation of $95.99B. That closing price of BMY’s stock is at a discount of -34.26% from its 52-week high price of $63.33 and is indicating a premium of 15.01% from its 52-week low price of $40.09. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 12.97 million shares which gives us an average trading volume of 14.89 million if we extend that period to 3-months.
For Bristol-Myers Squibb Co (BMY), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 2.64. Splitting up the data highlights that, out of 14 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 9 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Bristol-Myers Squibb Co (NYSE:BMY) trade information
Upright in the green during last session for gaining 1.59%, in the last five days BMY remained trading in the red while hitting it’s week-highest on Thursday, 07/10/25 when the stock touched $47.17 price level, adding 2.96% to its value on the day. Bristol-Myers Squibb Co’s shares saw a change of 16.58% in year-to-date performance and have moved -1.03% in past 5-day. Bristol-Myers Squibb Co (NYSE:BMY) showed a performance of -5.19% in past 30-days. Number of shares sold short was 33.61 million shares which calculate 2.58 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 66.5 to the stock, which implies a rise of 29.07% to its current value. Analysts have been projecting 65 as a low price target for the stock while placing it at a high target of 68. It follows that stock’s current price would drop -37.8% in reaching the projected high whereas dropping to the targeted low would mean a loss of -37.8% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around 479.95% while estimates for its earnings growth in next 5 years are of 72.31%.
BMY Dividends
Bristol-Myers Squibb Co is more likely to be releasing its next quarterly report on 2025-Apr-24 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt. With an annual yield of 5.22%, the share has a forward dividend of 2.46 which implies that company’s dividend yield remained growing in trailing twelve months while having a 5 year average dividend yield of 3.63%.
Bristol-Myers Squibb Co (NYSE:BMY)’s Major holders
Insiders are in possession of 0.07% of company’s total shares while institution are holding 82.11 percent of that, with stock having share float percentage of 82.17%. Investors also watch the number of corporate investors in a company very closely, which is 82.11% institutions for Bristol-Myers Squibb Co that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at BMY for having 186.57 million shares of worth $7.75 billion. And as of 2024-06-30, it was holding 9.2043 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 158.66 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.8273 of outstanding shares, having a total worth of $6.59 billion.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 64.1 shares of worth $3.02 billion or 3.15% of the total outstanding shares. The later fund manager was in possession of 56.39 shares on Mar 31, 2025 , making its stake of worth around $2.66 billion in the company or a holder of 2.77% of company’s stock.
